aneous between physician and patient. Also, last month, I visited the FDA and met with the director of the Center for Drug Evaluation and Research (Janet Woodcock) and her team. They want our Harvard program to team up with them and with the pharmaceutical industry to create a non-profit consortium that would

oughtfully in a recent New England 6 CONTROL NUMBER 257 - CONFIDENTIAL HOUSE_OVERSIGHT_024017 Journal of Medicine editorial (November 2013), where Janet Woodcock, MD, the FDA’s Director of the Center for Drug Evaluation and Research and other senior FDA staff members as co-authors, discussed the FDA’s new brea